Jazz Pharmaceuticals (NASDAQ:JAZZ) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZFree Report) in a research report released on Friday,Benzinga reports. They currently have a $200.00 price target on the specialty pharmaceutical company’s stock.

JAZZ has been the topic of a number of other research reports. Royal Bank of Canada boosted their target price on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an “outperform” rating in a report on Wednesday, October 23rd. Wells Fargo & Company dropped their target price on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a report on Thursday, August 1st. Cantor Fitzgerald reissued an “overweight” rating and issued a $140.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. JPMorgan Chase & Co. boosted their target price on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a report on Monday, August 19th. Finally, Piper Sandler reissued an “overweight” rating and issued a $163.00 target price (down previously from $166.00) on shares of Jazz Pharmaceuticals in a report on Thursday. Three analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $175.33.

Get Our Latest Report on Jazz Pharmaceuticals

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $126.67 on Friday. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals has a twelve month low of $99.06 and a twelve month high of $134.17. The stock has a 50 day moving average of $113.29 and a two-hundred day moving average of $110.62. The stock has a market cap of $7.66 billion, a P/E ratio of 17.84, a P/E/G ratio of 0.98 and a beta of 0.57.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of the business’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the sale, the senior vice president now directly owns 14,531 shares in the company, valued at approximately $1,573,707.30. The trade was a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $110.84, for a total value of $110,840.00. Following the sale, the chief executive officer now owns 428,976 shares in the company, valued at approximately $47,547,699.84. The trade was a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 6,110 shares of company stock valued at $720,160 over the last quarter. Company insiders own 4.20% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the company. EverSource Wealth Advisors LLC boosted its position in Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 97 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Jazz Pharmaceuticals by 65.5% in the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after acquiring an additional 116 shares in the last quarter. Arizona State Retirement System lifted its position in shares of Jazz Pharmaceuticals by 0.8% in the second quarter. Arizona State Retirement System now owns 16,580 shares of the specialty pharmaceutical company’s stock valued at $1,770,000 after acquiring an additional 130 shares in the last quarter. Coldstream Capital Management Inc. lifted its position in shares of Jazz Pharmaceuticals by 7.7% in the third quarter. Coldstream Capital Management Inc. now owns 2,300 shares of the specialty pharmaceutical company’s stock valued at $259,000 after acquiring an additional 165 shares in the last quarter. Finally, Itau Unibanco Holding S.A. lifted its position in shares of Jazz Pharmaceuticals by 63.2% in the third quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock valued at $49,000 after acquiring an additional 172 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

(Get Free Report)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Featured Stories

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.